Farmer K, Gunn T, Woodfield D G
N Z Med J. 1985 Oct 9;98(788):851-3.
Newborn infants of mothers who were chronic carriers of hepatitis Bs antigen (HBsAg) were randomly allocated to be treated or not treated with hyperimmune hepatitis B immunoglobulin (HBIg) at birth and six weeks and were then followed up to one year with sequential blood tests. Ninety percent of all untreated infants born of mothers positive for both HBsAg and hepatitis Be antigen became chronic carriers of HBsAg at one year. In contrast only 9% of infants treated with HBIg became HBsAg positive. Mothers who were HBsAg positive but hepatitis Be antigen negative only uncommonly infected their infants, with 6% being HBsAg positive at one year. Nearly all infections were in Pacific Islanders, Maoris or Asians. It is recommended that antenatal testing of these groups most at risk for hepatitis B virus spread, be initiated, followed by passive immunoprophylaxis with HBIg of infants born of HBsAg, HBeAg positive mothers.
母亲为乙肝表面抗原(HBsAg)慢性携带者的新生儿,在出生时及六周时被随机分配接受或不接受高效价乙肝免疫球蛋白(HBIg)治疗,随后进行连续血液检测并随访至一岁。母亲HBsAg和乙肝e抗原均呈阳性的所有未治疗婴儿中,90%在一岁时成为HBsAg慢性携带者。相比之下,接受HBIg治疗的婴儿中只有9%的HBsAg呈阳性。HBsAg呈阳性但乙肝e抗原呈阴性的母亲很少感染其婴儿,一岁时6%的婴儿HBsAg呈阳性。几乎所有感染都发生在太平洋岛民、毛利人或亚洲人身上。建议对这些乙肝病毒传播风险最高的群体进行产前检测,随后对HBsAg、HBeAg呈阳性母亲所生婴儿采用HBIg进行被动免疫预防。